

Clinical trial results for
early-stage non-small cell lung cancer (NSCLC) before and after surgery
Given before and after surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery
Clinical trial results for
early-stage non-small cell lung cancer (NSCLC) before and after surgery
Given before and after surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery
Actor portrayals.
This pre-surgery and post-surgery immunotherapy treatment may offer you an additional way to treat your condition. Before surgery, these treatments help shrink tumors. After surgery, they attack cancer cells that may remain “hidden” or hard to see and aim to keep them from coming back.
In a clinical trial of 461 people with early-stage NSCLC who were able to have surgery, 229 people were given OPDIVO + chemotherapy before surgery followed by OPDIVO alone after surgery, and 232 people were given platinum-based chemotherapy before surgery followed by placebo after surgery.
OPDIVO + chemotherapy and OPDIVO alone will not work for everyone. Individual results may vary.
It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)
For adults with early-stage non-small cell lung cancer (NSCLC) before and after surgery
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC that does not have an abnormal EGFR or ALK gene, and then may be continued alone after surgery to help prevent your lung cancer from coming back.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early stage lung cancer (called non-small cell lung cancer) that does not have an abnormal EGFR or ALK gene and then may be continued alone after surgery to help prevent your lung cancer from coming back.
It is not known if OPDIVO Qvantig is safe and effective in children.